<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01755325</url>
  </required_header>
  <id_info>
    <org_study_id>RJ-CYP001</org_study_id>
    <nct_id>NCT01755325</nct_id>
  </id_info>
  <brief_title>Phase III Study of Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult CML-CP Patients With Ph+</brief_title>
  <official_title>Phase III Study of Compound Realgar Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult Patients With Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Junmin Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is an open-label, randomized, double blind, placebo-controlled parallel-group,&#xD;
      multi-center study to evaluate the efficacy and safety of Compound realgar formula&#xD;
      Realgar-Indigo naturalis Tablet combined with Imatinib will be compared with imatinib alone&#xD;
      in adult patients with diagnosed Philadelphia chromosome-positive (Ph+) chronic myelogenous&#xD;
      leukemia in the chronic phase (CML-CP).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    not enough patients&#xD;
  </why_stopped>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the rate of Major molecular response（MMR） at 12 months</measure>
    <time_frame>12 months of follow-up from the start of treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">680</enrollment>
  <condition>Chronic Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>Compound realgar natural indigo Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Compound realgar natural indigo Tablet, 65mg/kg/d, from day1 to day14,every 4 weeks.&#xD;
imatinib,0.4g,qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo tablet,65mg/kg/d, from day1 to day14,every 4 weeks.&#xD;
imatinib 0.4g qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Compound realgar natural indigo Tablet</intervention_name>
    <description>Compound realgar natural indigo Tablet, 65mg/kg/d, from day1 to day14,every 4 weeks.&#xD;
imatinib,0.4g,qd</description>
    <arm_group_label>Compound realgar natural indigo Tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients, age &gt;= 18 years and &lt;= 75 years.&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group （ECOG） performance status (PS) score 0, 1, or 2.&#xD;
&#xD;
          3. Diagnosis of chronic myelogenous leukemia in chronic phase with confirmation of&#xD;
             Philadelphia chromosome positive.(Ph+ CML-CP)&#xD;
&#xD;
          4. Ph+ Chronic myelogenous leukemia in chronic phase patients within the first 12 months&#xD;
             of diagnosis.&#xD;
&#xD;
          5. Adequate end organ function as defined by:&#xD;
&#xD;
        (1). Alanine transaminase（ALT）, Aspartate transaminase（AST） &lt;=2.5 x upper limit of&#xD;
        normal（ULN）.&#xD;
&#xD;
        (2). Total bilirubin &lt;= 1.5 x ULN. (3).Cr &lt;= 1.5 x ULN. (4). Serum amylase and lipase &lt;=&#xD;
        1.5 x ULN. 6. Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Previously received or be receiving any of the following medical treatment for CML:&#xD;
&#xD;
          1. . Treatment with Busulfan within 1 day prior to study entry.&#xD;
&#xD;
          2. . Treatment with interferon-alpha within 2 days prior to study entry.&#xD;
&#xD;
          3. . Treatment with hydroxyurea within 1 day prior to study entry.&#xD;
&#xD;
          4. . Treatment with homoharringtonine within 14 days prior to study entry.&#xD;
&#xD;
          5. . Treatment with Cytosine arabinoside within 28 days prior to study entry.&#xD;
&#xD;
          6. . Surgery (Including hematopoietic stem cell transplantation therapy)&#xD;
&#xD;
          7. . Treatment with anthracyclines, or etoposide within 21 days prior to study entry.&#xD;
&#xD;
        2. Treatment with any tyrosine kinase inhibitor(s) or arsenic reagent prior to study entry&#xD;
        3. Patients who are: (a) pregnant, (b) breast feeding, (c) female or male of childbearing&#xD;
        potential unwilling to use contraceptive precautions throughout the trial.&#xD;
&#xD;
        4. Major surgery within 4 weeks prior to randomization or who have not recovered from prior&#xD;
        surgery.&#xD;
&#xD;
        5. Patients who have not recovered from toxic reaction of prior similar treatment evaluated&#xD;
        by investigators.&#xD;
&#xD;
        6. Impaired cardiac function including any one of the following:&#xD;
&#xD;
          1. LVEF &lt; 45%.&#xD;
&#xD;
          2. . Complete left bundle branch block.&#xD;
&#xD;
          3. . Use of a ventricular-paced pacemaker.&#xD;
&#xD;
          4. . Congenital long QT syndrome.&#xD;
&#xD;
          5. . History or presence of ventricular, clinically significant atrial tachyarrhythmias&#xD;
&#xD;
          6. . History or presence of clinically significant bradyarrhythmia.(heart rate&#xD;
             persistently less than 50/min)&#xD;
&#xD;
          7. . QTcF &gt; 450 msec for male or 470 msec for female.&#xD;
&#xD;
          8. . History of clinically documented myocardial infarction or unstable angina (during&#xD;
             the last 12 month).&#xD;
&#xD;
          9. .Any other severe heart disease. 7. Patients with active, uncontrolled psychiatric&#xD;
             disorders, without insight and the ability of exact expression.&#xD;
&#xD;
        8. Uncontrolled medical conditions:&#xD;
&#xD;
          1. .Uncontrolled diabetes with fasting blood-glucose &gt;200mg/dl (11.1mmol/L),or with&#xD;
             combined symptoms (nephropathy, peripheral neuropathy).&#xD;
&#xD;
          2. . Uncontrolled hypertension.&#xD;
&#xD;
          3. . Active or uncontrolled infection (persistent fever and worsening of the clinical&#xD;
             symptoms) 9. Impairment of gastrointestinal (GI) function or GI disease that may&#xD;
             significantly alter the absorption of the tested drug (e.g., ulcerative disease,&#xD;
             uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel&#xD;
             resection, or gastric bypass surgery).&#xD;
&#xD;
        10. History of chronic pancreatitis or history of acute pancreatitis within 1 year of study&#xD;
        entry.&#xD;
&#xD;
        11. Acute or chronic uncontrolled liver disease or severe renal disease considered&#xD;
        unrelated to CML.&#xD;
&#xD;
        12. Patients actively receiving therapy with strong CYP3A4 inhibitors, strong CYP3A4&#xD;
        inducers or any medications being potential to prolong the QT interval and the treatment&#xD;
        cannot be either discontinued or switched to a different medication prior to starting study&#xD;
        drug.&#xD;
&#xD;
        13. Treatment with other investigational agents (defined as not used in accordance with the&#xD;
        approved indication) within 4 weeks prior to randomization.&#xD;
&#xD;
        14. Known to be allergic to the study drugs, including crude drug or adjuvant. 15. As&#xD;
        investigators evaluate, the patients do not fit to join the study (such as with severe&#xD;
        complications) .&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saijuan Chen, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Runjin Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Union Hospital medical college Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The NO.1 People's Hospital of Huaian</name>
      <address>
        <city>Huaian</city>
        <state>Jiangsu</state>
        <zip>223002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital with Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Hospital Affiliated to Suzhou University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The FIrst Affiliated Hospital, College of Medicine, Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital, College of Medicine, Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Tumor Hospital of Jiangxi</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The NO.1 Hospital of Nanchang</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>333008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital-Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The FIrst Affiliated Hospital, College of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The People's Hospital of Peking University</name>
      <address>
        <city>Peking</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>December 18, 2012</study_first_submitted>
  <study_first_submitted_qc>December 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2012</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Junmin Li</investigator_full_name>
    <investigator_title>Director of hematology department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

